Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | PYGB | P11216 | 2/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514303 | 0.92 | LMNA (0.50) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL26666720 | 0.91 | LMNA (0.49) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL236109 | 0.89 | PDE3A (0.48) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL29773194 | 0.86 | PDE3A (0.46) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL10612101 | 0.86 | PDE3A (0.46) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| Phosphoric Acid SCHEMBL21465061 | 0.85 | PDE3A (0.45) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL30584639 | 0.85 | PDE3A (0.45) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL441998 | 0.85 | PDE3A (0.45) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL6060509 | 0.85 | PDE3A (0.45) | LMNAPDE3AMTORPDE4DSLC29A1 | |
| SCHEMBL9667470 | 0.85 | PDE3A (0.44) | LMNAPDE3AMTORPDE4DSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097706-B2 | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | Hammi Holdings Co., Ltd (KR) | 2012-01-17 | — | — | US | claimed |
| CN-101861320-A | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | HANMI PHARM IND CO LTD | 2010-10-13 | — | — | CN | claimed |
| US-20100249395-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-09-30 | — | — | US | claimed |
| EP-2220090-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2010-08-25 | — | — | EP | claimed |
| WO-2009066892-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2009-05-28 | — | — | WO | claimed |
| US-20250283094-A1 | Modified Nucleosides | SOMALOGIC OPERATING CO., INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20240158833-A1 | Compositions and Methods for Labeling Modified Nucleotides in Nucleic Acids | NEW ENGLAND BIOLABS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4323374-A1 | MODIFIED NUCLEOSIDES | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4294936-A1 | COMPOSITIONS AND METHODS FOR LABELING MODIFIED NUCLEOTIDES IN NUCLEIC ACIDS | New England Biolabs, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117242085-A | Modified nucleosides | 私募蛋白质体操作有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116925993-A | Genetically engineered strains and methods for enzyme-catalyzed production of cytidine acids | 北京量维生物科技研究院有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022178093-A1 | COMPOSITIONS AND METHODS FOR LABELING MODIFIED NUCLEOTIDES IN NUCLEIC ACIDS | NEW ENGLAND BIOLABS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-8097706-B2 | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | Hammi Holdings Co., Ltd (KR) | 2012-01-17 | — | — | US | disclosed |
| CN-101861320-A | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | HANMI PHARM IND CO LTD | 2010-10-13 | — | — | CN | disclosed |
| US-20100249395-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| EP-2220090-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009066892-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2009-05-28 | — | — | WO | disclosed |
| EP-1140967-A1 | TARGETED GENE TRANSFER USING G PROTEIN COUPLED RECEPTORS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039145-A1 | TARGETED GENE TRANSFER USING G PROTEIN COUPLED RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283094-A1 | Modified Nucleosides | NT5C3B, PNP, TYMP | LMNA 1230/4885PDE3A 1392/4885MTOR 4515/4885 |
| US-20100249395-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | TYMP, SI, DPYD | LMNA 3050/4885PDE3A 2731/4885MTOR 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.